Biogen Reports Positive Data of Felzartamab to Treat IgA Nephropathy (IgAN) at ASN Kidney Week 2024
Shots:
- Biogen reported data through an oral presentation at ASN 2024 from the P-II (IGNAZ) trial investigating Felzartamab (an investigational anti-CD38 mAb), to treat IgAN
- The P-II (IGNAZ) trial assessed the efficacy and safety of felzartamab in individuals with IgAN and a high risk of progressive kidney dysfunction who received a 9-dose regimen for 6mons.
- Results showed significant reductions in proteinuria and stable kidney function measured through UPCR and eGFR, respectively, for 24mons. with ~50% mean reduction in the UPCR and sustained treatment effect for over 18mons. after the last dose of felzartamab; the trial suggested cyclical administration over continuous dosing. Felzartamab was well tolerated and demonstrated a consistent safety profile
Ref: Biogen | Image: Biogen
Related News:- European Patent Office (EPO) Grants Approval to Biogen’s Tecfidera Patent
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
